[HTML][HTML] Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in canada: a descriptive analysis of real-world data

V Gitman, A Stavropoulos, V Saenz… - Multiple Sclerosis and …, 2022 - Elsevier
Objectives To report and describe the real-world use of ocrelizumab in women with multiple
sclerosis (MS) in Canada before and/or during pregnancy as well as their fetal outcomes …

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

F Barkhof, L Kappos, JS Wolinsky, DKB Li, A Bar-Or… - Neurology, 2019 - AAN Enterprises
Objective To assess the onset of ocrelizumab efficacy on brain MRI measures of disease
activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse …

[HTML][HTML] Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis

TL Vollmer, JA Cohen, E Alvarez, KV Nair… - Multiple Sclerosis and …, 2020 - Elsevier
Background Ocrelizumab is an approved MS treatment administered as two 300-mg
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours …

[HTML][HTML] Antibody therapies for progressive multiple sclerosis and for promoting repair

J Havla, R Hohlfeld - Neurotherapeutics, 2022 - Elsevier
Progressive multiple sclerosis (PMS) is clinically distinct from relapsing–remitting MS
(RRMS). In PMS, clinical disability progression occurs independently of relapse activity …

Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database

K Hellwig, C Oreja-Guevara, S Vukusic… - Multiple Sclerosis and …, 2023 - Elsevier
Background/Objective (s) Approved labels advise that women with multiple sclerosis (MS)
use contraception during treatment with ocrelizumab (OCR) and for 6–12 months thereafter; …

B cell depletion in the treatment of multiple sclerosis

KM Myhr, Ø Torkildsen, A Lossius, L Bø… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …

Anti-CD20 cell therapies in multiple sclerosis—a fixed dosing schedule for ocrelizumab is overkill

J Avasarala - Drug Target Insights, 2017 - journals.sagepub.com
Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based
singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech …

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability

JS Wolinsky, NJ Engmann, J Pei… - Multiple Sclerosis …, 2020 - journals.sagepub.com
Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease
progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary …

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary …

P Vermersch, C Oreja‐Guevara, A Siva… - European Journal of …, 2022 - Wiley Online Library
Background and purpose Using the treatment goal of “no evidence of disease
activity”(NEDA) incorporating magnetic resonance imaging (MRI) re‐baselining, we aimed …

Novel monoclonal antibodies for therapy of multiple sclerosis

B Knier, B Hemmer, T Korn - Expert opinion on biological therapy, 2014 - Taylor & Francis
Introduction: Monoclonal antibodies play an important role in the therapy of different
autoimmune diseases. With the introduction of natalizumab, the importance of monoclonal …